Join

Compare · CPNG vs LOGC

CPNG vs LOGC

Side-by-side comparison of Coupang Inc. (CPNG) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CPNG and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
  • CPNG is the larger of the two at $27.20B, about 557.6x LOGC ($48.8M).
  • Over the past year, CPNG is down 45.6% and LOGC is up 0.0% - LOGC leads by 45.6 points.
  • LOGC has been more active in the news (9 items in the past 4 weeks vs 3 for CPNG).
  • CPNG has more recent analyst coverage (25 ratings vs 5 for LOGC).
PerformanceCPNG-44.95%LOGC+0.00%
2025-06-13+0.00%2026-06-08
MetricCPNGLOGC
Company
Coupang Inc.
ContextLogic Inc.
Price
$15.45+1.98%
$7.05+1.00%
Market cap
$27.20B
$48.8M
1M return
-10.14%
+0.00%
1Y return
-45.64%
+0.00%
Industry
Catalog/Specialty Distribution
Catalog/Specialty Distribution
Exchange
NYSE
NASDAQ
IPO
2021
2020
News (4w)
3
9
Recent ratings
25
5
CPNG

Coupang Inc.

Coupang, Inc. owns and operates in e-commerce business through its mobile applications and Internet websites primarily in South Korea. It sells various products and services in the categories of home goods and décor products, apparel, beauty products, fresh food and groceries, sporting goods, electronics, and everyday consumables, as well as travel, and restaurant order and delivery services. The company was founded in 2010 and is based in Seoul, South Korea.

LOGC

ContextLogic Inc.

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.